Drugs / Mescaline
Mescaline
also known as
2-(3,4,5-trimethoxyphenyl)ethanamine · M (psychedelic) · mescaline hydrochloride · NSC-30419
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT04849013 Comparator | Aug 2021 → Mar 2023 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT04227756 Comparator | May 2020 → Sep 2022 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT02033707 Background | Apr 2014 → Feb 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mescaline | “Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid...” NCT02033707 ↗ |
| Known as | 2-(3,4,5-trimethoxyphenyl)ethanamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL26687 ↗ |
| Known as | M (psychedelic) | ChEMBL registry synonym — accepted as the source's own label CHEMBL26687 ↗ |
| Known as | mescaline hydrochloride | “The present study analyzed the pharmacokinetics, pharmacokinetic-pharmacodynamic relationship, and urinary recovery of oral mescaline hydrochloride.” PMID 40658345 ↗ Jul 2025 |
| Known as | NSC-30419 | ChEMBL registry synonym — accepted as the source's own label CHEMBL26687 ↗ |
| Modality | Small molecule | — CHEMBL26687 ↗ |
| Route | Oral | “Mescaline 300 mg or 500 mg per os, single dose” NCT04227756 ↗ |